Wednesday, Could 6, 2026
NIH-funded analysis identifies new mechanism of motion for next-generation weight-loss medicine
A Nationwide Institutes of Well being (NIH)-funded examine has discovered that an rising class of GLP-1 weight-loss medicine suppress consuming for pleasure, or hedonic feeding, in mice by modulating a reward circuit deep inside the mind. This newly charted pathway — separate from beforehand described mechanisms that broadly have an effect on urge for food — may very well be an avenue by which GLP-1s deal with different dysfunctions in reward processing, comparable to substance use dysfunction.
Within the examine, researchers on the College of Virginia particularly investigated small-molecule GLP-1 receptor agonists, such because the Meals and Drug Administration (FDA)-approved orforglipron, which could be taken orally and are cheaper to provide than their injectable counterparts.
“Because the accessibility of those drugs continues to rise and affected person uptake will increase, it’s essential that we perceive the neural mechanisms underlying the consequences we’re seeing,” mentioned Lorenzo Leggio, M.D., Ph.D., scientific director of NIH’s Nationwide Institute on Drug Abuse (NIDA).
Earlier analysis has extensively explored the consequences of bigger peptide GLP-1s, comparable to semaglutide, within the mind, discovering that they suppress hunger-driven consuming by participating networks within the hypothalamus and hindbrain. Till now, scientists have had a a lot much less agency grasp on how small-molecule GLP-1 medicine work.
To achieve a greater understanding, the authors modified the GLP-1 receptors of mice with gene-editing strategies, making them extra humanlike.
The group administered orforglipron or one other small-molecule drug, danuglipron, and recognized mind areas the place they induced exercise. Whereas the GLP-1s affected acquainted territory, in addition they triggered exercise within the central amygdala, a area related to want that’s deeper within the mind than scientists beforehand thought GLP-1s may straight attain.
Additional experiments confirmed that, as soon as activated, the central amygdala decreased dopamine launch into key hubs of the mind’s reward circuitry throughout hedonic feeding.
“We’ve identified that GLP-1 medicine suppress feeding habits pushed by power demand. Now it appears oral small-molecule GLP-1s additionally dial again consuming for pleasure by participating a mind reward circuit,” mentioned co-corresponding writer Ali Guler, Ph.D, a professor of biology on the College of Virginia.
In response to scientists, the pure subsequent query is whether or not these next-generation GLP-1s can even tone down cravings for issues aside from meals. In follow-up research they hope to dive into their results on substance use dysfunction particularly.
NIH supported this analysis by way of the Nationwide Institute of Neurological Problems and Stroke (NINDS) grants R01NS111220, R01NS122834, and R01NS120702, the Nationwide Institute of Basic Medical Sciences (NIGMS) grant R35GM140854, the Nationwide Coronary heart, Blood, and Lung Institute (NHLBI) grant R01HL153916, and the Nationwide Most cancers Institute (NCI) grant P30CA044579.
This examine was not accomplished as a scientific trial related to an software and has not been assessed by FDA for product approval for acknowledged indications.
In regards to the Nationwide Institute on Drug Abuse (NIDA): NIDA is a part of the Nationwide Institutes of Well being, U.S. Division of Well being and Human Companies. NIDA helps many of the world’s analysis on the well being elements of drug use and habit. The Institute carries out a big number of packages to tell coverage, enhance apply, and advance habit science. For extra details about NIDA and its packages, go to www.nida.nih.gov.
In regards to the Nationwide Institutes of Well being (NIH): NIH, the nation’s medical analysis company, contains 27 Institutes and Facilities and is a part of the U.S. Division of Well being and Human Companies. NIH is the first federal company conducting and supporting primary, scientific, and translational medical analysis, and is investigating the causes, remedies, and cures for each frequent and uncommon illnesses. For extra details about NIH and its packages, go to www.nih.gov.
NIH…Turning Discovery Into Well being®
Reference
Elizabeth N. Godschall, Taha Bugra Gungul, Isabelle R. Sajonia, et al. A Mind Reward Circuit Inhibited By Subsequent-Technology Weight Loss Medicine in Mice. Nature. 2026. DOI: 10.1038/s41586-026-10444-4
